Tonix stock jumps on collaboration for mpox vaccine candidate [Seeking Alpha]
GeoVax Labs, Inc. (GOVX)
NASDAQ:AMEX Investor Relations:
geovax.com/contact-geovax.html
Company Research
Source: Seeking Alpha
TNX-801, which is based on the horsepox virus, is currently in preclinical development for the prevention of mpox and smallpox. The spread of Mpox, also known as monkeypox, was recently declared a public health emergency of international concern by the World Health Organization. Bilthoven is a unit of vaccine maker Cyrus Poonawalla Group, which also includes the Serum Institute of India. The European Union has selected Bilthoven as one of its vaccine manufacturing companies for its pandemic preparedness program, according to Tonix Bavarian Nordic ( OTCPK:BVNKF OTCPK:BVNRY ) and GeoVax Labs ( GOVX ) are also developing vaccines for mpox, while Emergent Biosciences ( EBS ) has an approved vaccine and treatment for smallpox, a related disease. Mpox test makers include Co-Diagnostics ( CODX ), Roche ( OTCQX:RHHBY ), Abbott Laboratories ( ABT ) and Applied DNA Sciences ( APDN Recommended For You More Trending News Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
GOVX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GOVX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GOVX alerts
High impacting GeoVax Labs, Inc. news events
Weekly update
A roundup of the hottest topics
GOVX
News
- GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia [Yahoo! Finance]Yahoo! Finance
- GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic LeukemiaGlobeNewswire
- GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.MarketBeat
- Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges [Yahoo! Finance]Yahoo! Finance
- GeoVax Reports Third Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswire
GOVX
Earnings
- 11/12/24 - Beat
GOVX
Analyst Actions
- 11/15/24 - HC Wainwright
GOVX
Sec Filings
- 11/18/24 - Form 8-K
- 11/14/24 - Form SC
- 11/13/24 - Form 8-K
- GOVX's page on the SEC website